Abstract
Esptein-Barr virus (EBV) is a ubiquitous gammaherpesvirus that persists in carriers as a lifelong, mostly asymptomatic infection. EBV is associated with a variety of lymphomas and lymphoproliferative disorders. In this review we provide an update of the relevant literature on EBV-associated lymphoproliferative disorders, with particular emphasis on epidemiology, pathogenesis, and novel treatment approaches.
MeSH terms
-
Adoptive Transfer
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Antiviral Agents / therapeutic use
-
Brain Neoplasms / radiotherapy
-
Brain Neoplasms / virology
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Epstein-Barr Virus Infections* / drug therapy
-
Epstein-Barr Virus Infections* / epidemiology
-
Herpesvirus 4, Human / isolation & purification
-
Herpesvirus 4, Human / pathogenicity
-
Humans
-
Immunocompromised Host
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / therapeutic use
-
Immunosuppressive Agents / adverse effects
-
Immunotherapy
-
Lymphocyte Subsets / virology
-
Lymphoma / drug therapy
-
Lymphoma / epidemiology
-
Lymphoma / virology*
-
Lymphoma, AIDS-Related / virology
-
Lymphoproliferative Disorders / drug therapy
-
Lymphoproliferative Disorders / epidemiology
-
Lymphoproliferative Disorders / virology*
-
Multicenter Studies as Topic
-
Organ Transplantation
-
Postoperative Complications / drug therapy
-
Postoperative Complications / epidemiology
-
Postoperative Complications / virology
-
RNA, Viral / analysis
-
Rituximab
-
Viral Proteins / analysis
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antiviral Agents
-
Immunologic Factors
-
Immunosuppressive Agents
-
RNA, Viral
-
Viral Proteins
-
Rituximab